AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17512226
Drug: Redo saphenofemoral
RxNorm normalized name: Redox-phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Redo saphenofemoral ligation and great saphenous vein stripping with PTFE patch
Trial: 17512226
Drug: Redo saphenofemoral
RxNorm normalized name: Redox-phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Redo saphenofemoral ligation and great saphenous vein stripping without PTFE patch
Trial: 17512226
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (with and without PTFE patch)
Trial: 7802219
Drug: Single medial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single medial injection using prilocaine 3% with felypressin
Trial: 7802219
Drug: Two injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections using prilocaine 3% with felypressin
Trial: 3293874
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day carprofen
Trial: 3293874
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day carprofen
Trial: 3293874
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day carprofen
Trial: 3293874
Drug: 800 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day carprofen
Trial: 3293874
Drug: Carprofen concentrations
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carprofen concentrations greater than 10 micrograms/ml
Trial: 3293874
Drug: Carprofen concentrations
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carprofen concentrations below 1.9 micrograms/ml
Trial: 3293874
Drug: Carprofen (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carprofen (various doses)
Trial: 3293874
Drug: Carprofen (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carprofen (up to 600 mg daily)
Trial: 25881455
Drug: Chuanhuang No.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chuanhuang No.1 Recipe (CHR), 400 mL each time, one dose per day for 24 weeks
Trial: 25881455
Drug: Losartan Potassium,
RxNorm normalized name: Losartan Potassium, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan Potassium, 50-100 mg per day for 24 weeks
Trial: 11871364
Drug: Short-acting beta2-agonist
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting beta2-agonist (salbutamol, n=41)
Trial: 11871364
Drug: Long-acting beta2-agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting beta2-agonist (formoterol, n=46)
Trial: 24621065
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg zinc daily for 12 weeks
Trial: 23909679
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol treatment
Trial: 11359594
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia with intravenous propofol sedation (SA)
Trial: 9304087
Drug: 2% clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% clindamycin vaginal cream (100 mg/day for 7 days)
Trial: 9304087
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin (2 g/day for 7 days)
Trial: 29108797
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor plus NRTI group (lopinavir 400 mg with ritonavir 100 mg, twice per day plus two or three clinician-selected NRTIs)
Trial: 29108797
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor plus raltegravir group (lopinavir plus raltegravir 400 mg twice per day)
Trial: 29108797
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor monotherapy group (lopinavir monotherapy plus raltegravir induction for first 12 weeks, re-intensified to combination therapy after week 96)
Trial: 25357218
Drug: Osteopathy (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathy (3 sessions at 15, 30, and 45 days after infliximab infusion)
Trial: 18375318
Drug: ACE‐Is (ramipril,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE‐Is (ramipril, 1.25 mg twice a day from the day after the operation)
Trial: 15262194
Drug: Atorvastatin 20mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg with placebo (group AP)
Trial: 12577430
Drug: Naoreqing (NRQ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naoreqing (NRQ) oral liquid
Trial: 12577430
Drug: Naoreqing (NRQ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naoreqing (NRQ) oral liquid plus western medicine
Trial: 9701524
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg b.d. (group PMC 500)
Trial: 9701524
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg b.d. (group PMC 250)
Trial: 29036256
Drug: Oral minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral minocycline HCl extended-release tablets (approximately 1 mg/kg)
Trial: 29036256
Drug: Topical minocycline
RxNorm normalized name: minocycline Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minocycline foam 4% (4-g maximal-use dose) applied once daily for 21 days
Trial: 19221257
Drug: Whole-body irradiated
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body irradiated with a 0.7-MED of UV-B daily on 10 consecutive days followed by a single dose of 3 MEDs on a small body area
Trial: 19221257
Drug: Whole body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole body irradiated with 120 J/m2 solar-simulated radiation for 10 consecutive days, then single-dose UV-B exposure of 3 MEDs on a small body area after 24 hours
Trial: 19221257
Drug: Irradiated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiated with a single UV-B dose of 3 MEDs on a small body area
Trial: 19221257
Drug: Irradiated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiated with a single UV-B dose of 4 MEDs on a small body area
Trial: 14656270
Drug: Adjuvant platinum-containing
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant platinum-containing chemotherapy
Trial: 7510316
Drug: Tianeptine 12.5
RxNorm normalized name: tianeptine 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine 12.5 mg single dose and 12 weeks treatment up to 37.5 mg daily
Trial: 3774011
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course of chemotherapy (cyclophosphamide, 5 mg/kg/day for 6 days iv)
Trial: 3774011
Drug: Continued chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued chemotherapy for 1 year (for node-positive patients)
Trial: 27458288
Drug: Selinexor (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor (60 mg flat dose) administered twice per week (days 1 and 3) on a 3 weeks on, 1 week off schedule
Trial: 20467648
Drug: No HBO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No HBO therapy
Trial: 8876070
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg cetirizine (CTZ)
Trial: 8876070
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg pseudoephedrine retard (PER)
Trial: 8876070
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5 mg cetirizine and 120 mg pseudoephedrine retard (COM)
Trial: 1362377
Drug: Vasoactive agents
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive agents
Trial: 3925486
Drug: Diazepam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.25 mg/kg oral)
Trial: 18559301
Drug: Valerian/hops fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian/hops fluid extract (2 ml diluted in 50 ml water, administered 15 minutes before EEG recording)
Trial: 18559301
Drug: Placebo (similar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (similar smelling placebo, 2 ml diluted in 50 ml water, administered 15 minutes before EEG recording)
Trial: 11217678
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg DKPT t.i.d. (n = 97)
Trial: 11217678
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg TRAM t.i.d. (n = 95)
Trial: 9291421
Drug: BAY x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY x 7195 (500 mg, single oral dose)
Trial: 2873760
Drug: Atracurium, 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium, 1.0 mg/kg
Trial: 2873760
Drug: Vecuronium, 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium, 0.1 mg/kg
Trial: 2873760
Drug: Vecuronium, 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium, 0.2 mg/kg
Trial: 2873760
Drug: Atracurium, 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium, 1.0 mg/kg (rapid sequence induction)
Trial: 2873760
Drug: Vecuronium, 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium, 0.2 mg/kg (rapid sequence induction)
Trial: 29470308
Drug: IAI 2
RxNorm normalized name: Intravitreal aflibercept injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAI 2 mg every 4 weeks until Week 16 then 8-week dosing (2q8)
Trial: 26927286
Drug: Acetaminophen 4g
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 4g daily for 7 days
Trial: 17042248
Drug: Caffeinated tube
RxNorm normalized name: Sus scrofa fallopian tube preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated tube food (200 mg)
Trial: 10775736
Drug: Controlled-release oxybutynin
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release oxybutynin
Trial: 9068331
Drug: Propofol (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (n = 26, median dose 157 mg over 70 s)
Trial: 9068331
Drug: Etomidate (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (n = 25, median dose 16.2 mg in 57 s)
Trial: 3518527
Drug: Purified and
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified and standardized Cladosporium herbarum allergen preparation (active treatment)
Trial: 31331339
Drug: Routine follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine follow-up (RFU) with one extra medical visit and additional visits to the Cardiology and Respiratory Medicine Clinics 1 and 3 months postoperatively
Trial: 28836375
Drug: Motivational Interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Interviewing (MI) session before periodontal treatment
Trial: 28836375
Drug: Conventional educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional educational intervention and non-surgical periodontal therapy
Trial: 24681572
Drug: Nitrate-rich concentrated
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich concentrated beetroot juice (NIT; nitrate dosage, approximately 9.7 mmol·d)
Trial: 17549677
Drug: Levofloxacin formulation
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin formulation product after oral administration
Trial: 16208152
Drug: HCTZ 25
RxNorm normalized name: HCTZ 25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ 25 mg added to olmesartan 20 mg
Trial: 16208152
Drug: Olmesartan/HCTZ 20/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan/HCTZ 20/12.5 mg
Trial: 16208152
Drug: Olmesartan/HCTZ 20/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan/HCTZ 20/25 mg
Trial: 9893775
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release oral salbutamol (CR) 8 mg b.d. for > or = 3 days
Trial: 9893775
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled salmeterol xinafoate (SX) 100 micrograms b.d. for > or = 3 days
Trial: 15465995
Drug: High-dose omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose omega-3 fatty acids
Trial: 10770448
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (100-300 mg/day)
Trial: 10817105
Drug: Paroxetine (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (10-40 mg/day)
Trial: 8788597
Drug: FK453 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK453 (50 mg)
Trial: 8788597
Drug: FK453 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK453 (200 mg)
Trial: 6436935
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg sustained release theophylline
Trial: 6436935
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg sustained release theophylline
Trial: 6436935
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg and 450 mg sustained release theophylline
Trial: 30696471
Drug: Automated VR
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated VR cognitive treatment
Trial: 20183394
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy processes measured by the Working Alliance Inventory‐Short Form
Trial: 17973865
Drug: N(G)-monomethyl-L-arginine (L-NMMA)
RxNorm normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)-monomethyl-L-arginine (L-NMMA) at 1 mmol/L
Trial: 17973865
Drug: Asymmetric dimethylarginine
RxNorm normalized name: dimethylamine
DrugBank: N,N-dimethylarginine (DB01686)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asymmetric dimethylarginine (ADMA) at 1 mmol/L
Trial: 17973865
Drug: L-leucine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-leucine at 1 mmol/L
Trial: 11502777
Drug: Low-dose hydrocortisone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hydrocortisone therapy (32 patients treated)
Trial: 11502777
Drug: Low-dose hydrocortisone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hydrocortisone therapy (in responders)
Trial: 11502777
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (in responders)
Trial: 7508066
Drug: diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diet and fluid plus indapamide 2.5 mg/day (group B)
Trial: 7508066
Drug: diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diet and fluid plus indapamide 2.5 mg/day plus allopurinol 300 mg/day (group C)
Trial: 3106449
Drug: Sodium Cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Cromoglycate (SCG) (10 mg)
Trial: 2685081
Drug: Amiodarone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (200 mg every 8 h for 2 weeks, then 200 mg/day)
Trial: 31976548
Drug: Tetramethylpyrazine (TMP)
RxNorm normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetramethylpyrazine (TMP) 100 mg·kg‐1 ·day‐1 in animal models (Sprague-Dawley rats)
Trial: 31976548
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of TMP (100 mg, t.i.d. for 16 weeks) in a small cohort of patients with PAH or CTEPH
Trial: 22911223
Drug: bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine plus epinephrine 100 μg
Trial: 22911223
Drug: bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine plus epinephrine 200 μg
Trial: 15198841
Drug: Weekly fructosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly fructosamine testing in addition to daily glucose monitoring (Group 1)
Trial: 15198841
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care of daily glucose monitoring (Group 2)
Trial: 3567122
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of salbutamol orally five times daily
Trial: 24818633
Drug: COBRA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA therapy (methotrexate 7.5 mg/week, sulfasalazine 2 g/day, with initial prednisolone 60 mg/day)
Trial: 24818633
Drug: COBRA-light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA-light therapy (methotrexate increased to 25 mg/week with initial prednisolone 30 mg/day)
Trial: 23278964
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive fractional bipolar radiofrequency (FRF) treatment
Trial: 18199590
Drug: Fructose drink
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose drink (60 g in 500 ml)
Trial: 18199590
Drug: Glucose drink
RxNorm normalized name: Dextrose 15 GM Oral Solution [RELION GLUCOSE DRINK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose drink (60 g in 500 ml)
Trial: 16442153
Drug: BAY 12‐9566
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 12‐9566 (tanomastat) 800 mg p.o. b.i.d.
Trial: 14615615
Drug: Anticoagulation (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation (5-10 day course of full-dose low-molecular-weight heparin followed by 3 months of lower-dose low-molecular-weight heparin)
Trial: 11739865
Drug: Liver paste
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver paste (3.0, 7.5, or 15 mg vitamin A)
Trial: 11739865
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplement (3.0, 7.5, or 15 mg vitamin A)
Trial: 9239992
Drug: Leucine supplementation
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine supplementation (50.0 +/- 3.3 mg/kg body weight per day)
Trial: 31529084
Drug: Oral sugar
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sugar enriched expressed breastmilk (EBM)
Trial: 31529084
Drug: IV dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dextrose therapy (IVDx)
Trial: 31188728
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (finasteride plus doxazosin)
Trial: 23248072
Drug: Opicapone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 10 mg
Trial: 23248072
Drug: Opicapone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 100 mg
Trial: 23248072
Drug: Opicapone 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 200 mg
Trial: 23248072
Drug: Opicapone 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 400 mg
Trial: 23248072
Drug: Opicapone 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 800 mg
Trial: 23248072
Drug: Opicapone 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 1200 mg
Trial: 23248072
Drug: Opicapone 50
RxNorm normalized name: opicapone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 50 mg with high-fat meal
Trial: 23248072
Drug: Opicapone 50
RxNorm normalized name: opicapone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 50 mg fasting
Trial: 18490378
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis with sulfamethoxazole/trimethoprim for 2 years
Trial: 18490378
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis with sulfamethoxazole/trimethoprim
Trial: 12670781
Drug: cilomilast (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilomilast (15 mg)